Tuesday | BioMed Central
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or...
We investigated this combination as neoadjuvant therapy for locally advanced pancreatic cancer .
A randomized phase III study of radiotherapy alone or with...
A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282.
Therapy of locally unresectable pancreatic carcinoma: a randomized...
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose radiation alone, moderate dose radiation , and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Gaithersburg drug-maker signs deal for European market
Wellstat Therapeutics is selling to a London company certain rights, plus an option for marketing rights, for its experimental drug used as an antidote in cancer chemotherapy.
CytRx commences INNO-206 Phase 2 clinical trial for pancreatic cancer
CytRx Corporation , a biopharmaceutical company specializing in oncology , today announced the initiation of a Phase 2 clinical trial evaluating the preliminary efficacy and safety of INNO-206 in patients with advanced pancreatic ductual adenocarcinomas who have progressed after receiving two prior therapies.
Also on Topix